Immune checkpoint inhibitor-induced pure red cell aplasia: a nationwide retrospective case series and literature review.

HOME
>
論文・技術情報
>
Immune checkpoint inhibitor-induced pure red cell aplasia: a nationwide retrospective case series and literature review.

Immune checkpoint inhibitor-induced pure red cell aplasia: a nationwide retrospective case series and literature review.

アブストラクト	Immune checkpoint inhibitors (ICIs) may lead to rare but severe hematological adverse events, including pure red cell aplasia (ICI-PRCA). We conducted a nationwide retrospective national case-series and compiled our data with patients from the VigiBase international pharmacovigilance database. We gathered 16 cases of ICI-PRCA Among all the grade >/= 3 adverse event reported in VigiBase, PRCA was more than two times more reported with ICI compared to all other drugs ROR [IC95%] 2.43 [1.89;3.13]. We identified 15 additional patients in our literature review. Half of the patients were women (52%), median age 63 years (range: 29-90). ICIs were mostly used in melanoma (48%) and lung adenocarcinoma (16%) in metastatic stage (29%). Monoclonal antibody targeting programmed death-1 (PD-1) alone was involved in 61% of cases. The median time from ICI initiation to symptoms onset was 63 days (range: 28-465). Grade >/=3 anemia in found in all cases (100%). Thirteen patients (42%) were treated with corticosteroids as monotherapy with an ORR of 69%. Thirteen patients (42%) required additional therapy. ICI therapy was discontinued in all patients and rechallenge was attempted in 4 patients (13%), with recurrence in one case. ICI-PRCA is a severe and early-onset immune adverse event. Both systemic steroids and cicloporine A seems effective in these immune-related forms.
ジャーナル名	Annals of hematology
Pubmed追加日	2026/1/20
投稿者	Bisiou, Sirivanh; Lobbes, Herve; Palassin, Pascale; Allouchery, Marion; Comont, Thibault; Rivet, Valerian
組織名	Department of Medecine and Clinical Immunology, Montpellier University Hospital,;Montpellier, France.;Internal Medicine Department, Clermont Ferrand University Hospital,;Clermont-Ferrand, France.;Department of Medical Pharmacology and Toxicology, Regional Pharmacovigilance;Center, CHRU Montpellier, Montpellier, France.;Clinical Pharmacology and Vigilance Department, Poitiers University Hospital,;Poitiers, France.;Department of Internal Medicine and Immunopathology, Institut du Cancer de;Toulouse, Toulouse, France.;Department of Internal Medicine and Immunopathology, Toulouse University;Hospital, Toulouse, France.;Toulouse, Toulouse, France. valerian.rivet@gmail.com.;Hospital, Toulouse, France. valerian.rivet@gmail.com.
Pubmed リンク	https://www.ncbi.nlm.nih.gov/pubmed/41554971/